tetano
Editor, Senior Moderator
Hum Vaccin. 2011 Aug 1;7(8). [Epub ahead of print]
Efficacy and safety of the H1N1 monovalent vaccine in renal-transplant recipients and dialysis patients.
Beaudreuil S, Krivine A, Hebibi H, Ducot B, Mazet AA, Taouffik Y, Seidowsky A, Jacquet A, Kristian Lorenzo H, Charpentier B, Francois H, Durrbach A.
Source
Nephrology Department, University Hospital; Le Kremlin Bicetre, France.
Abstract
Background: The (H1N)1v influenza virus infection emerged in 2009 as a serious disease in targeted populations. Herein, we report on the tolerability and efficacy of (anti-H1N1)v vaccination in dialysis and transplant patients. Methods: 18 renal-transplant recipients (RTR) and 19 dialysis patients (DP) (12 patients treated with peritoneal dialysis (PDP), 7 patients treated with haemodialysis (HDP)) were enrolled. DPs received one monovalent H1N1 adjuvanted-vaccine injection, and RTRs received two unadjuvanted vaccine injections within a 21-day period. Serologic response was defined as a haemagglutination inhibition titre of > 40 (seroprotection) and/or at least a four-fold increase in antibody titre from baseline (seroconversion). Results: Seroprotection rate after vaccination was greater in DPs than RTRs (p = 0.007), as was seroconversion (p = 0.001). Serologic response was similar in PDPs and HDPs. Conclusions:. Serologic response was satisfactory in DPs, whichever dialysis mode (DPD or HDP). It was low in RTRs as compared to DPs. Abstract word count 149.
PMID:
21847012
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21847012
Efficacy and safety of the H1N1 monovalent vaccine in renal-transplant recipients and dialysis patients.
Beaudreuil S, Krivine A, Hebibi H, Ducot B, Mazet AA, Taouffik Y, Seidowsky A, Jacquet A, Kristian Lorenzo H, Charpentier B, Francois H, Durrbach A.
Source
Nephrology Department, University Hospital; Le Kremlin Bicetre, France.
Abstract
Background: The (H1N)1v influenza virus infection emerged in 2009 as a serious disease in targeted populations. Herein, we report on the tolerability and efficacy of (anti-H1N1)v vaccination in dialysis and transplant patients. Methods: 18 renal-transplant recipients (RTR) and 19 dialysis patients (DP) (12 patients treated with peritoneal dialysis (PDP), 7 patients treated with haemodialysis (HDP)) were enrolled. DPs received one monovalent H1N1 adjuvanted-vaccine injection, and RTRs received two unadjuvanted vaccine injections within a 21-day period. Serologic response was defined as a haemagglutination inhibition titre of > 40 (seroprotection) and/or at least a four-fold increase in antibody titre from baseline (seroconversion). Results: Seroprotection rate after vaccination was greater in DPs than RTRs (p = 0.007), as was seroconversion (p = 0.001). Serologic response was similar in PDPs and HDPs. Conclusions:. Serologic response was satisfactory in DPs, whichever dialysis mode (DPD or HDP). It was low in RTRs as compared to DPs. Abstract word count 149.
PMID:
21847012
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21847012